

**REMARKS**

Claims 6-27 are pending.

Applicants thank the Examiner for the courtesies extended to their representative during the Personal Interview of January 25, 2007, during which the Examiner asserted that the claims were rejected as being overly broad. Specifically, the Examiner stated that the current language, "corresponding to," rendered the claim rejectable over prior art.

Accordingly, the present claims have been amended to clarify that which is being claimed. Specifically, claim 6 has been amended to recite a recombinant polypeptide largely corresponding to FP6. As described in the specification and drawings, FP6 includes a segment (E), which is 68 AA in length and a second segment (G), which is a (repeating) segment of 12 AA in length. Similarly, claim 21 has been amended to recite a recombinant polypeptide largely corresponding to FP3, i.e., including segments A, B and C. Support for these claims can be found in SEQ ID NO. 1.

Applicants respectively submit that the present amendments place the claims in condition for allowance. However, should the Examiner disagree, he is invited to contact the undersigned to schedule an interview prior to the issuance of a subsequent Office Action, such that the claims can be further amended.

If any additional fee is necessary to make this paper timely or complete, it may be charged to the undersigned's deposit account number 19-4375.

Respectfully submitted,



PNL/EPR  
Attorney Docket No.: PNL 21311A

Peter N. Lalos  
Registration No. 19,789

STEVENS, DAVIS, MILLER & MOSHER, L.L.P.  
1615 L Street, N.W., Suite 850  
Washington, D.C. 20036  
Telephone: (202) 785-0100  
Facsimile: (202) 408-5200 or (202) 408-5088  
Date: May 14, 2007